\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationonline
ProgrammesOn 5 July 2024, the European Institute of Innovation and Technology (EIT) and the European Innovation Council and SMEs Executive Agency (EISMEA) invite you to an informative webinar to learn more about the European Prize for Women Innovators.
The European Prize for Women Innovators is an initiative powered by EIT and EIC. It celebrates the outstanding achievements of women entrepreneurs from across the EU and Horizon Europe associated countries who are driving positive change for people and the planet through their innovative ventures.
If you're considering joining the competition but feel like you need more information, this webinar is for you! Get ready to apply to the 2025 European Prize for Women Innovators by joining us online on 5 July 2024, from 11.00 to 12.00 CEST. During this one-hour session, we will:
Dive into the details of the application and award procedures for each prize category
Listen to a testimonial by a winner of the 2024 European Prize for Women Innovators
Get tips for preparing prize applications from a former Jury Member
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
